Truck transport: on the Wagon

A few weeks ago, while travelling by Konkan Railway, I happened to see rake after rake of...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
Somany Ceramics Q4 net profit up 6% at Rs8.4 crore

Total income of the tile maker stood at Rs276.25 crore for the fourth quarter ended March 2012 as against Rs238.88 crore for the same period year ago

New Delhi: Tile maker Somany Ceramics reported 6.4% increase in its net profit at Rs8.46 crore for the quarter ended March 2012, mainly on account of robust sales of digital and glazed vitrified tiles, reports PTI.

The company had posted a net profit of Rs7.95 crore for the quarter ended March 2011 Somany Ceramics said in a statement.

Total income of the company stood at Rs276.25 crore for the fourth quarter ended March 2012 as against Rs238.88 crore for the same period year ago.

The company's board of directors have also recommended a dividend of Rs0.8 per share for the full year.

Net profit of the company for the year ended March 2012 stood at Rs24.75 crore as against Rs23.43 crore for the corresponding period previous fiscal.

Commenting on the results, Somany Ceramics JMD Abhishek Somany said, "Higher share of revenue from value added products including digital tiles and glazed vitrified tiles helped company reduce the adverse impact of increase in the cost of energy, raw materials, borrowings and rupee depreciation."

The company had total income of Rs873.23 crore for the year ended March 2012. It was Rs714.33 crore for the year ago period.

Shares of Somany Ceramics were trading at Rs 42.05 on BSE, down 5.82% from its previous

User

Aurobindo Pharma gets US nod for generic anti-HIV drug

Aurobindo Pharma plans to launch the products manufactured at its Hyderabad facility soon in the US market

New Delhi: Aurobindo Pharma on Wednesday said it has received final approval from the US health regulator for its generic Nevirapine tablets and oral suspension used for treating human immunodeficiency virus (HIV), reports PTI.

The company has received final approval from the United States Food and Drug Administration (USFDA) for its Nevirapine tablets in the strength of 200 mg and Nevirapine oral suspension in the strength of 50 mg/5ml, Aurobindo Pharma said in a statement.

The company plans to launch the products manufactured at its Hyderabad facility soon in the US market, it added.

According to IMS health data the products have a market size of about $125 million for the twelve months ending December 2011, Aurobindo Pharma said.

Nevirapine tablets and oral suspension are generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune tablets and oral suspension in the same strengths.

"The products are indicated as part of antiretroviral combination therapy for the treatment of HIV infected adults," it added.

The company said it currently has 151 abbreviated new drug application (ANDA) approvals from the USFDA.

Shares of Aurobindo Pharma were today trading at Rs111.50 in the afternoon trade on BSE, up 1.23% from its previous close.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)